Evidence map›Paper›PMID 30574042›Full record

ReviewEJIFCC2018

Surrogate Biomarkers for Monitoring Healthcare Quality for Chronic Diseases Such as Diabetes Care.

Diler Aslan

Open access · greenAbstract readReview
In one paragraph

Review in EJIFCC, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Diler AslanDepartment of Medical Biochemistry, Medical Faculty, Pamukkale University, Denizli, Turkey.
Pamukkale University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some laboratory tests or biomarkers are used as surrogate outcomes for health care effectiveness. HbA1c is defined as a surrogate biomarker since HbA1c values have been approved to be used in predictions of clinically important complications of diabetes mellitus. With the advance of information technology (IT) the real life data are aggregating as electronic health records (EHRs). About 70-85% of individuals admitted to hospitals have laboratory test results. As such, medical laboratories are the data centers in the hospitals. The test results can be used for assessment of health care delivered, especially for chronic diseases. This information provides insights of healthcare services, and can be used to enhance for individual and population well-being, research, and education. This article focuses on the importance of using laboratory tests results as outcome measures for specific population health status that are important in assessing the quality of health care services. The findings from our studies on the diabetic care quality is presented.

Indexed as

diabetes careHbA1chealthcare qualitysurrogate outcomes

Identifiers

PMID30574042
PMCPMC6295596
OpenAlexW3020993950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.